{"id":"NCT02470780","sponsor":"University of Cincinnati","briefTitle":"Treating Bacterial Overgrowth in Parkinson's Disease","officialTitle":"Treating Bacterial Overgrowth in Parkinson's Disease","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2015-12","primaryCompletion":"2017-08","completion":"2017-08","firstPosted":"2015-06-12","resultsPosted":"2024-03-01","lastUpdate":"2024-03-01"},"enrollment":4,"design":{"allocation":"RANDOMIZED","model":"SEQUENTIAL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson's Disease","Small Intestinal Bacterial Overgrowth"],"interventions":[{"type":"DRUG","name":"Rifaximin","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Three-month follow-up","type":"EXPERIMENTAL"},{"label":"Six-month follow-up","type":"EXPERIMENTAL"}],"summary":"This study investigates the effect of treating Small Intestinal Bacterial Overgrowth (SIBO) in patients with Parkinson's Disease (PD). It will test the hypothesis that treating SIBO with the antibiotic rifaximin will improve motor complications in previously SIBO-positive PD patients.","primaryOutcome":{"measure":"Change in \"Off\" Time as Measured by Patient Diary","timeFrame":"baseline to 1 month and 3 months; new baseline at 3 months to 4 months and 6 months","effectByArm":[{"arm":"Rifaximin (3-month Follow-up)","deltaMin":-1.4,"sd":2},{"arm":"Placebo Then Rifaximin","deltaMin":-2.8,"sd":0.7}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":4},"commonTop":[]}}